Randomized controlled clinical trial investigating Erlotinib for the treatment of chronic hepatitis C virus infectio
- Conditions
- MedDRA version: 14.1Level: PTClassification code 10019755Term: Hepatitis chronic activeSystem Organ Class: 10019805 - Hepatobiliary disordersC hepatitisTherapeutic area: Diseases [C] - Virus Diseases [C02]
- Registration Number
- EUCTR2012-002069-36-FR
- Lead Sponsor
- Hôpitaux Universitaires de Strasbourg
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Authorised-recruitment may be ongoing or finished
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 12
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Main Objective: evaluating short term efficacy and safety of erlotinib in patient infected with genotype 1 C hepatitis virus ;Secondary Objective: - assessement of viral kinetic<br>- erlotinib phamacokinitic evaluation<br>- functional analysis of HCV quasispecies and viral resistance evaluation ;Primary end point(s):
- Secondary Outcome Measures
Name Time Method